Industry Expert Insights In Navigating The Complex Supply Chain For Cell And Gene Therapies

Cell and gene therapies (CGTs) hold immense promise for treating a wide range of diseases, but their complex supply chain presents significant logistical challenges. Unlike traditional pharmaceuticals, CGTs often involve personalized treatments, requiring meticulous handling and transportation of patient-derived materials. From maintaining precise temperature controls to ensuring secure and timely delivery, the supply chain for CGTs demands careful planning and execution.

This article delves into the unique demands of the CGT supply chain, highlighting the need for early integration of logistical considerations into clinical development. It explores the role of logistics providers in ensuring safe and efficient transport, the impact of regulatory frameworks on CGT accessibility, and the importance of standardization and harmonization across regions.

By examining the insights shared by industry experts during Cencora's ThinkLive Cell and Gene Therapy Summit 2024, this article sheds light on the challenges and opportunities in navigating this complex landscape. It underscores the importance of collaboration between researchers, clinicians, logistics providers, and regulatory bodies to overcome these hurdles and ultimately improve patient access to life-saving CGTs.